BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 25556489)

  • 1. miR-340 reverses cisplatin resistance of hepatocellular carcinoma cell lines by targeting Nrf2-dependent antioxidant pathway.
    Shi L; Chen ZG; Wu LL; Zheng JJ; Yang JR; Chen XF; Chen ZQ; Liu CL; Chi SY; Zheng JY; Huang HX; Lin XY; Zheng F
    Asian Pac J Cancer Prev; 2014; 15(23):10439-44. PubMed ID: 25556489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MiR-141 Activates Nrf2-Dependent Antioxidant Pathway via Down-Regulating the Expression of Keap1 Conferring the Resistance of Hepatocellular Carcinoma Cells to 5-Fluorouracil.
    Shi L; Wu L; Chen Z; Yang J; Chen X; Yu F; Zheng F; Lin X
    Cell Physiol Biochem; 2015; 35(6):2333-48. PubMed ID: 25896253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulated miR-182 increases drug resistance in cisplatin-treated HCC cell by regulating TP53INP1.
    Qin J; Luo M; Qian H; Chen W
    Gene; 2014 Apr; 538(2):342-7. PubMed ID: 24447717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. lncRNA KRAL reverses 5-fluorouracil resistance in hepatocellular carcinoma cells by acting as a ceRNA against miR-141.
    Wu L; Pan C; Wei X; Shi Y; Zheng J; Lin X; Shi L
    Cell Commun Signal; 2018 Aug; 16(1):47. PubMed ID: 30119680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of Growth-Arrest-Specific Transcript 5 Improved Cisplatin Sensitivity in Hepatocellular Carcinoma Through Sponging miR-222.
    Zhao P; Cui X; Zhao L; Liu L; Wang D
    DNA Cell Biol; 2020 Apr; 39(4):724-732. PubMed ID: 32213078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of miR-33a-5p in Hepatocellular Carcinoma: A Possible Mechanism for Chemotherapy Resistance.
    Meng W; Tai Y; Zhao H; Fu B; Zhang T; Liu W; Li H; Yang Y; Zhang Q; Feng Y; Chen G
    Med Sci Monit; 2017 Mar; 23():1295-1304. PubMed ID: 28291769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of miR-363 increases drug resistance in cisplatin-treated HepG2 by dysregulating Mcl-1.
    Ou Y; Zhai D; Wu N; Li X
    Gene; 2015 Nov; 572(1):116-122. PubMed ID: 26143754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein phosphatase 2A-B55δ enhances chemotherapy sensitivity of human hepatocellular carcinoma under the regulation of microRNA-133b.
    Zhuang Q; Zhou T; He C; Zhang S; Qiu Y; Luo B; Zhao R; Liu H; Lin Y; Lin Z
    J Exp Clin Cancer Res; 2016 Apr; 35():67. PubMed ID: 27074866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mir-1307 regulates cisplatin resistance by targeting Mdm4 in breast cancer expressing wild type P53.
    Wang X; Zhu J
    Thorac Cancer; 2018 Jun; 9(6):676-683. PubMed ID: 29697201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deregulation of UCA1 expression may be involved in the development of chemoresistance to cisplatin in the treatment of non-small-cell lung cancer via regulating the signaling pathway of microRNA-495/NRF2.
    Li C; Fan K; Qu Y; Zhai W; Huang A; Sun X; Xing S
    J Cell Physiol; 2020 Apr; 235(4):3721-3730. PubMed ID: 31583720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poor expression of microRNA-135b results in the inhibition of cisplatin resistance and proliferation and induces the apoptosis of gastric cancer cells through MST1-mediated MAPK signaling pathway.
    Zhou J; Chen Q
    FASEB J; 2019 Mar; 33(3):3420-3436. PubMed ID: 30576232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-381 Reverses Multidrug Resistance by Negative Regulation of the
    Pu B; Yu X; Cao Y; Li Y; Tang L; Xia J
    DNA Cell Biol; 2021 Dec; 40(12):1584-1596. PubMed ID: 34931867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-193b acts as a cisplatin sensitizer via the caspase-3-dependent pathway in HCC chemotherapy.
    Yin W; Nie Y; Zhang Z; Xie L; He X
    Oncol Rep; 2015 Jul; 34(1):368-74. PubMed ID: 25997995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancer-bound Nrf2 licenses HIF-1α transcription under hypoxia to promote cisplatin resistance in hepatocellular carcinoma cells.
    Jin X; Gong L; Peng Y; Li L; Liu G
    Aging (Albany NY); 2020 Dec; 13(1):364-375. PubMed ID: 33290263
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Akdemir B; Nakajima Y; Inazawa J; Inoue J
    Mol Cancer Res; 2017 Nov; 15(11):1570-1578. PubMed ID: 28760781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The effects of microRNA-7 on proliferation and invasion of hepatocellular carcinoma HepG2 cells].
    Qin AD; Liu XX; Li J; Liu J; Li YS
    Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):406-411. PubMed ID: 29936764
    [No Abstract]   [Full Text] [Related]  

  • 17. Comprehensive analysis of microRNA-regulated protein interaction network reveals the tumor suppressive role of microRNA-149 in human hepatocellular carcinoma via targeting AKT-mTOR pathway.
    Zhang Y; Guo X; Xiong L; Yu L; Li Z; Guo Q; Li Z; Li B; Lin N
    Mol Cancer; 2014 Nov; 13():253. PubMed ID: 25424347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Up-regulation of miR-877 induced by paclitaxel inhibits hepatocellular carcinoma cell proliferation though targeting FOXM1.
    Huang X; Qin J; Lu S
    Int J Clin Exp Pathol; 2015; 8(2):1515-24. PubMed ID: 25973036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines.
    Zhuo L; Liu J; Wang B; Gao M; Huang A
    Oncol Rep; 2013 Feb; 29(2):555-62. PubMed ID: 23229111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of lncRNA KCNQ1OT1 on autophagy and drug resistance of hepatocellular carcinoma cells by targeting miR-338-3p.
    Zhong W; Dai Q; Huang Q
    Cell Mol Biol (Noisy-le-grand); 2020 Jun; 66(3):191-196. PubMed ID: 32538770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.